Home > Focus Areas > Focus on Infectious Disease > Post
  • Saved

3yr
Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study

Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study

Source : https://www.cureus.com/articles/133667-amiodarone-for-the-treatment-of-arrhythmias-in-covid-19-patients-does-not-increase-the-risk-of-pulmonary-fibrosis-a-retrospective-cohort-study

Amiodarone is a class III antiarrhythmic medication used to treat atrial and ventricular tachyarrhythmias. Pulmonary fibrosis from amiodarone use is a well-documented side effect. Pre-COVID-19 pandemic studies have shown that amiodarone-induced pulmonary fibrosis occurs in 1%-5% of patients and usually occurs between 12 to 60 months after initiation.



The clinical factors associated with the development of pulmonary fibrosis in both groups included a history of preexisting interstitial lung disease (ILD) (p=0.001), exposure to prior radiation therapy (p=0.021), and higher severity of COVID-19 illness (p

  • 3yr
    Amiodarone is a class III antiarrhythmic medication utilized in the rhythm control of both atrial and ventricular tachyarrhythmias. Its mechanism works to prolong the action potential duration by blocking potassium channels.

You might also like